Evidence map›Paper›PMID 40038918›Full record

ArticleCardiovascular research2025

Targeted delivery of TAPI-1 via biomimetic nanoparticles ameliorates post-infarct left ventricle function and remodelling.

Qing Chen, Yang Yu, Lei Tong, Robert M Weiss, Shun-Guang Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Qing ChenDepartment of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Yang YuDepartment of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Lei TongDepartment of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Robert M WeissDepartment of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Shun-Guang WeiDepartment of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.ORCID 0000-0003-4404-4059

Funding

Novel Role of Interleukin-17 in Sympathetic Activation in Heart FailureR01HL155091 · NHLBI · UNIVERSITY OF IOWA · PI WEI, SHUNGUANG · 2021 to 2025
$2.9M
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.R01HL139521 · NHLBI · UNIVERSITY OF IOWA · PI WEI, SHUNGUANG · 2018 to 2022
$1.9M
High-Resolution Research UltrasoundS10OD019941 · OD · UNIVERSITY OF IOWA · PI WEISS, ROBERT M · 2015 to 2015
$298k
NHLBI NIH HHS R01 HL139521NHLBI NIH HHS R01 HL155091NIH HHS 1S10-OD019941NIH HHS HL-155091NIH HHS R01 HL-139521NIH HHS S10 OD019941
6 · The paper itself

Abstract

aimsThe potential of nanoparticles as effective drug delivery tools for treating failing hearts in heart failure remains a challenge. Leveraging the rapid infiltration of neutrophils into infarcted hearts after myocardial infarction (MI), we developed a nanoparticle platform engineered with neutrophil membrane proteins for the targeted delivery of TAPI-1, a TACE/ADAM17 inhibitor, to the inflamed myocardium, aiming to treat cardiac dysfunction and remodelling in rats with MI. METHODS AND

resultsNeutrophil-mimic liposomal nanoparticles (Neu-LNPs) were constructed by integrating synthesized liposomal nanoparticles with LPS-stimulated neutrophil membrane fragments and then loaded with TAPI-1. MI rats were treated with TAPI-1 delivered via Neu-LNPs for 4 weeks. Left ventricular function was assessed by echocardiography and cardiac fibrosis was evaluated post-treatment. The novel Neu-LNPs maintained typical nanoparticle features, but with increased biocompatibility. Neu-LNPs demonstrated improved targeting ability and cellular internalization, facilitated by LFA1/Mac1/ICAM-1 interaction. Neu-LNPs displayed higher accumulation and cellular uptake by macrophages and cardiomyocytes in infarcted hearts post-MI, with a sustained duration. Treatments with TAPI-1-Neu-LNPs demonstrated greater protection against myocardial injury and cardiac dysfunction in MI rats compared to untargeted TAPI-1, along with reduced cardiac collagen deposition and expression of fibrosis biomarkers as well as altered immune cell compositions within the hearts.

conclusionsTargeted treatment with TACE/ADAM17 inhibitor delivered via biomimetic nanoparticles exhibited pronounced advantages in improving left ventricle function, mitigating cardiac remodelling, and reducing inflammatory responses within the infarcted hearts. This study underscores the effectiveness of Neu-LNPs as a drug delivery strategy to enhance therapeutic efficacy in clinical settings.

Indexed as

Anti-Inflammatory AgentsBiomimetic MaterialsMyocardial InfarctionNanoparticle Drug Delivery SystemNanoparticlesVentricular Function, LeftVentricular RemodelingADAM17 ProteinAnimalsBiomimeticsDisease Models, AnimalFibrosisLiposomesMaleMyocytes, CardiacNeutrophil InfiltrationADAM17 ProteinAnti-Inflammatory AgentsLiposomesNanoparticle Drug Delivery SystemDrug deliveryInflammationMyocardial infarctionNanotechnologyTACE/ADAM17

Identifiers

PMID40038918
PMCPMC12101320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.